Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats

Diabetologia

Volumn 58, Issue 5, 2015, Pages 1081-1090

  Taveau, Christopher ^a,b,c   Chollet, Catherine ^a,b,c   Waeckel, Ludovic ^a,b,c   Desposito, Dorinne ^a,b,c   Bichet, Daniel G ^d   Arthus, Marie Françoise ^d   Magnan, Christophe ^c,e   Philippe, Erwann ^c,e   Paradis, Valerie ^c,f   Foufelle, Fabienne ^a,b,c   Hainault, Isabelle ^a,b,c   Enhorning, Sofia ^g,h   Velho, Gilberto ^a,b,c   Roussel, Ronan ^a,c,i   Bankir, Lise ^a,b,c   Melander, Olle ^g,h   Bouby, Nadine ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^e Groupe Hospitalier Pitié Salpêtrière   (France)

^f BEAUJON HOSPITAL   (France)

^g LUND UNIVERSITY   (Sweden)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ BICHAT HOSPITAL   (France)

Author keywords

Glucose metabolism; Hydration; Lipid metabolism; Liver; Vasopressin

Indexed keywords

GLUCOSE BLOOD LEVEL; INDOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; RELCOVAPTAN; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL; BLOOD; DRINKING; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; MALE; METABOLISM; OBESITY; PHYSIOLOGY; ZUCKER RAT;

ANIMALS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BLOOD GLUCOSE; DRINKING; FATTY LIVER; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INDOLES; MALE; OBESITY; PYRROLIDINES; RATS, ZUCKER; VASOPRESSINS;

EID: 84939976662     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3496-9     Document Type: Article

References (53)

1. Zerbe RL, Vinicor F, Robertson GL (1979) Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 28:503–508
2. Brooks DP, Nutting DF, Crofton JT, Share L (1989) Vasopressin in rats with genetic and streptozocin-induced diabetes. Diabetes 38:54–57
3. Yi SS, Hwang IK, Kim YN et al (2008) Enhanced expressions of arginine vasopressin (Avp) in the hypothalamic paraventricular and supraoptic nuclei of type 2 diabetic rats. Neurochem Res 33:833–841
4. Hems DA, Whitton PD, Ma GY (1975) Metabolic actions of vasopressin, glucagon and adrenalin in the intact rat. Biochim Biophys Acta 411:155–164
5. Rofe AM, Williamson DH (1983) Metabolic effects of vasopressin infusion in the starved rat. Reversal of ketonaemia. Biochem J 212:231–239
6. Spruce BA, McCulloch AJ, Burd J et al (1985) The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol (Oxf) 22:463–468
7. Lee B, Yang C, Chen TH, al-Azawi N, Hsu WH (1995) Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. Am J Physiol 269:E1095–E1100
8. Yibchok-Anun S, Cheng H, Chen TH, Hsu WH (2000) Mechanisms of AVP-induced glucagon release in clonal alpha-cells in-R1-G9: involvement of Ca(2+)-dependent and -independent pathways. Br J Pharmacol 129:257–264
9. Abu-Basha EA, Yibchok-Anun S, Hsu WH (2002) Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 51:1184–1190
10. Gillies GE, Linton EA, Lowry PJ (1982) Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299:355–357
11. Serradeil-Le Gal C, Wagnon J, Simiand J et al (2002) Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N, N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 300:1122–1130
12. Aoyagi T, Birumachi J, Hiroyama M et al (2007) Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 148:2075–2084
13. Fujiwara Y, Hiroyama M, Sanbe A et al (2007) Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol 584:235–244
14. Nakamura K, Aoyagi T, Hiroyama M et al (2009) Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance. Eur J Pharmacol 613:182–188
15. Nakamura K, Yamashita T, Fujiki H et al (2011) Enhanced glucose tolerance in the Brattleboro rat. Biochem Biophys Res Commun 405:64–67
16. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112–119
17. Saleem U, Khaleghi M, Morgenthaler NG et al (2009) Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 94:2558–2564
18. Enhorning S, Wang TJ, Nilsson PM et al (2010) Plasma copeptin and the risk of diabetes mellitus. Circulation 121:2102–2108
19. Roussel R, Fezeu L, Bouby N et al (2011) Low water intake and risk for new-onset hyperglycemia. Diabetes Care 34:2551–2554
20. Bardoux P, Bichet DG, Martin H et al (2003) Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 18:497–506
21. Bankir L, Bouby N, Ritz E (2013) Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 9:223–239
22. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT (2010) Copeptin, a surrogate marker of vasopressin, is associated with albuminuria in a large population cohort. Kidney Int 77:29–36
23. Velho G, Bouby N, Hadjadj S et al (2013) Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 36:3639–3645
24. Bouby N, Bachmann S, Bichet D, Bankir L (1990) Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 258:F973–F979
25. Bichet DG, Arthus MF, Barjon JN, Lonergan M, Kortas C (1987) Human platelet fraction arginine-vasopressin. Potential physiological role. J Clin Invest 79:881–887
26. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402–408
27. Bergmeyer HU (ed) (1974) Methods of enzymatic analysis. Academic, New York
28. Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L (2008) Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol 19:1721–1731
29. Morel A, O’Carroll AM, Brownstein MJ, Lolait SJ (1992) Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356:523–526
30. Zerbe RL, Miller JZ, Robertson GL (1991) The reproducibility and heritability of individual differences in osmoregulatory function in normal human subjects. J Lab Clin Med 117:51–59
31. Hems DA, Whitton PD (1973) Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. Biochem J 136:705–709
32. Wideman CH, Murphy HM (1993) Modulatory effects of vasopressin on glucose and protein metabolism during food-restriction stress. Peptides 14:259–261
33. Enhorning S, Leosdottir M, Wallstrom P et al (2009) Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am J Clin Nutr 89:400–406
34. Lang F, Busch GL, Ritter M et al (1998) Functional significance of cell volume regulatory mechanisms. Physiol Rev 78:247–306
35. Cryer PE (2012) Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153:1039–1048
36. Guillon G, Grazzini E, Andrez M et al (1998) Vasopressin: a potent autocrine/paracrine regulator of mammal adrenal functions. Endocr Res 24:703–710
37. Morgan NG, Shipp CC, Exton JH (1983) Studies on the mechanism of inhibition of hepatic cAMP accumulation by vasopressin. FEBS Lett 163:277–281
38. Chabardes D, Imbert-Teboul M, Elalouf JM (1999) Functional properties of Ca2+-inhibitable type 5 and type 6 adenylyl cyclases and role of Ca2+ increase in the inhibition of intracellular cAMP content. Cell Signal 11:651–663
39. Itoh S, Yamada S, Mori T et al (2006) Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor. Am J Physiol Endocrinol Metab 291:E147–E151
40. Koschorreck M, Gilles ED (2008) Mathematical modeling and analysis of insulin clearance in vivo. BMC Syst Biol 2:43
41. Bouby N, Ahloulay M, Nsegbe E, Dechaux M, Schmitt F, Bankir L (1996) Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 7:842–851
42. Bardoux P, Martin H, Ahloulay M et al (1999) Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci U S A 96:10397–10402
43. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA (2004) Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 24:644–649
44. Wendel AA, Li LO, Li Y, Cline GW, Shulman GI, Coleman RA (2010) Glycerol-3-phosphate acyltransferase 1 deficiency in ob/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity. Diabetes 59:1321–1329
45. Moon YA, Liang G, Xie X et al (2012) The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab 15:240–246
46. Kirk CJ, Hems DA (1979) The control by vasopressin of carbohydrate and lipid metabolism in the perfused rat liver. Biochim Biophys Acta 583:474–482
47. Ma GY, Hems DA (1975) Inhibition of fatty acid synthesis and stimulation of glycogen breakdown by vasopressin in the perfused mouse liver. Biochem J 152:389–392
48. Assimacopoulos-Jeannet F, Denton RM, Jeanrenaud B (1981) Stimulation of hepatic lipogenesis and acetyl-coenzyme A carboxylase by vasopressin. Biochem J 198:485–490
49. Azizi M, Iturrioz X, Blanchard A et al (2008) Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol 19:1015–1024
50. Hus-Citharel A, Bouby N, Frugiere A, Bodineau L, Gasc JM, Llorens-Cortes C (2008) Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int 74:486–494
51. Galanth C, Hus-Citharel A, Li B, Llorens-Cortes C (2012) Apelin in the control of body fluid homeostasis and cardiovascular functions. Curr Pharm Des 18:789–798
52. Knauf C, Drougard A, Fournel A, Duparc T, Valet P (2013) Hypothalamic actions of apelin on energy metabolism: new insight on glucose homeostasis and metabolic disorders. Horm Metab Res 45:928–934
53. Principe A, Melgar-Lesmes P, Fernandez-Varo G et al (2008) The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 48:1193–1201